Navigation Links
Food and Drug Administration (FDA) Joins Pharma IQ's Viral Safety 2011 Conference
Date:8/22/2011

LONDON, August 22, 2011 /PRNewswire/ --

Santosh Nanda, Microbiologist/ Primary Reviewer, CBER, FDA and Rebecca Sheets, Vaccine Scientific and Regulatory Specialist, NIH/NIAID have announced their official participation at the Viral Safety 2011 conference due to take place from the 17th October to 19th October 2011 in NH München Dornach, Munich, Germany.

This year's conference has expanded its focus from solely viral safety to encompass mycoplasma, TSE and bacteria. The event will have a strong focus on prevention and regulatory compliance as well as offering a nature of discussion based and interactive sessions.

Systematically Characterising Adventitious Agent Tests for Biologics

At the conference, Rebecca Sheets will be discussing the policy perspective on adapting new testing methodologies, she will assess the breadth and sensitivity of routine adventitious agent tests and will cover the harmonisation of test methods (both existing and emerging).

On the other hand, Santosh Nanda will be sharing a regulatory perspective on how to evaluate the Safety of New Flu Vaccine Development Methods, he will assess the risks of the cell-based development process and will also Investigate the challenges and benefits of utilising cell based vaccine development and developing regulatory guidance to govern the process.

The Viral Safety 2011 conference aims at creating effective strategies to mitigate risk and enable prompt remediation of viral, prion and mycoplasma contamination - it will provide an interactive forum for learning best practices, keeping abreast of new developments and forging lasting business relationships.

20 biotech and biopharma experts are getting together this October to share updates and insights on how to escape contamination and get your products to market safely, speedily and successfully.

To view the conference programme (including full speaker and session information) visit

http://www.adventitiousagentsevent.com/redForms.aspx?id=553186&pdf_form=1


Find event details and registration information on http://www.adventitiousagentsevent.com/news2 or email enquire@iqpc.co.uk

Media contact: Veronica Araujo, +44(0)20-7368-9748, veronica.araujo@iqpc.co.uk or visit  http://www.adventitiousagentsevent.com/news2

 

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Veronica Araujo (veronica.araujo@iqpc.co.uk)


'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
6. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
10. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
11. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)... YORK , Sept. 8, 2017 Dealmed ... largest independent supplier of medical equipment, supplies, drugs, vaccines, ... it has entered into an agreement to acquire Vantage ... equipment based in Holtsville, New York ... specializes in supplying new and emerging medical practices, will ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):